Search Results - "Moroose, Rebecca L"

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer by Bardia, Aditya, Mayer, Ingrid A, Vahdat, Linda T, Tolaney, Sara M, Isakoff, Steven J, Diamond, Jennifer R, O’Shaughnessy, Joyce, Moroose, Rebecca L, Santin, Alessandro D, Abramson, Vandana G, Shah, Nikita C, Rugo, Hope S, Goldenberg, David M, Sweidan, Ala M, Iannone, Robert, Washkowitz, Sarah, Sharkey, Robert M, Wegener, William A, Kalinsky, Kevin

“…In an extension of a basket trial focusing on triple-negative breast cancer, patients who received sacituzumab govitecan, an antibody–drug conjugate, had a…”
Get full text

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer by Bardia, Aditya, Mayer, Ingrid A, Diamond, Jennifer R, Moroose, Rebecca L, Isakoff, Steven J, Starodub, Alexander N, Shah, Nikita C, O'Shaughnessy, Joyce, Kalinsky, Kevin, Guarino, Michael, Abramson, Vandana, Juric, Dejan, Tolaney, Sara M, Berlin, Jordan, Messersmith, Wells A, Ocean, Allyson J, Wegener, William A, Maliakal, Pius, Sharkey, Robert M, Govindan, Serengulam V, Goldenberg, David M, Vahdat, Linda T

“…Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an…”
Get full text

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer by Slamon, Dennis J., Fasching, Peter A., Hurvitz, Sara, Chia, Stephen, Crown, John, Martín, Miguel, Barrios, Carlos H., Bardia, Aditya, Im, Seock-Ah, Yardley, Denise A., Untch, Michael, Huang, Chiun-Sheng, Stroyakovskiy, Daniil, Xu, Binghe, Moroose, Rebecca L., Loi, Sherene, Visco, Frances, Bee-Munteanu, Valerie, Afenjar, Karen, Fresco, Rodrigo, Taran, Tetiana, Chakravartty, Arunava, Zarate, Juan Pablo, Lteif, Agnes, Hortobagyi, Gabriel N.

“…Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor…”
Get full text

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer by Bardia, Aditya, Mayer, Ingrid A, Diamond, Jennifer R, Moroose, Rebecca L, Isakoff, Steven J, Starodub, Alexander N, Shah, Nikita C, O'Shaughnessy, Joyce, Kalinsky, Kevin, Guarino, Michael, Abramson, Vandana, Juric, Dejan, Tolaney, Sara M, Berlin, Jordan, Messersmith, Wells A, Ocean, Allyson J, Wegener, William A, Maliakal, Pius, Sharkey, Robert M, Govindan, Serengulam V, Goldenberg, David M, Vahdat, Linda T

“…Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an…”
Get full text

A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01) by Hurvitz, Sara A, Allen, Heather J, Moroose, Rebecca L, Chan, David, Hagenstad, Christopher, Applebaum, Steven H, Patel, Giribala, Hu, Eddie H, Ryba, Nancy, Lin, Lii-Shin, Wang, HeJing, Glaspy, John, Slamon, Dennis J, Kabbinavar, Fairooz

“…Abstract Introduction Addition of the antiangiogenic agent bevacizumab to paclitaxel significantly improves response rates and progression-free survival for…”
Get full text

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial by Slamon, Dennis J., Stroyakovskiy, Daniil, Yardley, Denise A., Huang, Chiun-Sheng, Fasching, Peter A., Crown, John, Bardia, Aditya, Chia, Stephen, Im, Seock-Ah, Martin, Miguel, Loi, Sherene, Xu, Binghe, Hurvitz, Sara A., Barrios, Carlos, Untch, Michael, Moroose, Rebecca L., Visco, Fran, Fresco, Rodrigo, Taran, Tetiana, Hortobagyi, Gabriel N.

“…LBA500 Background: RIB + ET has demonstrated significant survival benefits in pre- and postmenopausal pts with HR+/HER2− metastatic BC. To investigate whether…”
Get full text

Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC) by O'Shaughnessy, Joyce, Moroose, Rebecca L., Babu, Sunil, Baramidze, Kakhaber, Chan, David, Leitner, Stuart P., Nemsadze, Gia, Ordentlich, Peter, Quaranto, Christine, Meyers, Michael L., González Graf, Valeria, Smith, Taunya J., Bee-Munteanu, Valerie, Fresco, Rodrigo, Slamon, Dennis J.

“…Abstract only 1014 Background: Chemotherapy remains as the only standard treatment option for aTNBC in second and subsequent lines. Entinostat (ENT) is an…”
Get full text

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC) by Bardia, Aditya, Diamond, Jennifer Robinson, Vahdat, Linda T., Tolaney, Sara M., O'Shaughnessy, Joyce, Moroose, Rebecca L., Mayer, Ingrid A., Abramson, Vandana Gupta, Juric, Dejan, Sharkey, Robert M., Washkowitz, Sarah A., Wegener, William A., Goldenberg, David M., Kalinsky, Kevin

“…Abstract only…”
Get full text

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2− early breast cancer by Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi

“…Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor…”
Get full text

Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results by Bardia, Aditya, Diamond, Jennifer Robinson, Messersmith, Wells A., Mayer, Ingrid A., Isakoff, Steven J., Abramson, Vandana Gupta, Berlin, Jordan, Starodub, Alexander, O'Shaughnessy, Joyce, Kalinsky, Kevin, Moroose, Rebecca L., Shah, Nikita C., Juric, Dejan, Shapiro, Geoffrey, Guarino, Michael J., Ocean, Allyson J., Wilhelm, Francois, Sharkey, Robert M., Goldenberg, David M., Vahdat, Linda T.

“…Abstract only LBA509 Notice of Retraction: “Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38…”
Get full text

Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552) by Bardia, Aditya, Starodub, Alexander, Moroose, Rebecca L, Mayer, Ingrid A, Diamond, Jennifer R, Chuang, Ellen, Govindan, Serengulam V, Sharkey, Robert M, Maliakal, Pius, Wegener, William A, Hamburger, Steven A, Ocean, Allyson J, Goldenberg, David M, Vahdat, Linda T

“…Abstract Background: TNBC, comprising 15-20% of all invasive breast cancers, represents an aggressive phenotype with high risk of recurrence and mortality…”
Get full text

Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results by Goldenberg, David M, Vahdat, Linda T, Starodub, Alexander N, Bardia, Aditya, Chuang, Ellen, Moroose, Rebecca L, Diamond, Jennifer R, Sharkey, Robert M, Maliakal, Pius P, Hamburger, Steven A, Ocean, Allyson J

“…Abstract Despite major advances in breast cancer treatment, TNBC, which comprises approximately 15% of all breast cancer cases, continues to have a poor…”
Get full text

Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results by Bardia, Aditya, Diamond, Jennifer Robinson, Messersmith, Wells A., Mayer, Ingrid A., Isakoff, Steven J., Abramson, Vandana Gupta, Berlin, Jordan, Starodub, Alexander, O'Shaughnessy, Joyce, Kalinsky, Kevin, Moroose, Rebecca L., Shah, Nikita C., Juric, Dejan, Shapiro, Geoffrey, Guarino, Michael J., Ocean, Allyson J., Wilhelm, Francois, Sharkey, Robert M., Goldenberg, David M., Vahdat, Linda T.

“…Abstract only…”
Get full text

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience by Bardia, Aditya, Vahdat, Linda T., Diamond, Jennifer Robinson, Starodub, Alexander, Moroose, Rebecca L., Isakoff, Steven J., Ocean, Allyson J., Berlin, Jordan, Messersmith, Wells A., Thomas, Sajeve Samuel, Wilhelm, Francois, Wegener, William A., Maliakal, Pius P, Sharkey, Robert M., Goldenberg, David M., Mayer, Ingrid A.

“…Abstract only…”
Get full text